In implementation of the Decree of the Ministry of Health of 6 February 2021 (published in the Offical Gazette (GU) no. 32 of 8/2/21), the Italian Medicines Agency has established the monitoring registry of monoclonal antibodies for treatment of COVID-19. Therefore, this press release makes public the results of the monitoring through the AIFA registry, relating to the antibodies currently available: bamlanivimab (AIFA Resolution published in the GU no. 58 of 09.03.2021), bamlanivimab and etesevimab (AIFA Resolution published in the GU no. 66 of 17.03.2021), casirivimab and imdevimab (AIFA Resolution published in the GU no. 71 of 23.03.2021).
The centres authorised by the Regions to compile the AIFA registry are available at the following link.